This finding is contrary to Mishra et al., which showed the blockage of NLRP3 inflammasome activation and IL-1β release after inhibiting PAD activity with Cl-amidine in bone marrow-derived macrophages (BMDMs) [9]. This evidence concerns the gene IL1B and peripheral arterial disease.